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Neutrophils are vital for antimicrobial defense; however, their role
during viral infection is less clear. Furthermore, the molecular regula-
tion of neutrophil fate and function at the viral infected sites is largely
elusive. Here we report that BCL6 deficiency in myeloid cells exhibited
drastically enhanced host resistance to severe influenza A virus (IAV)
infection. In contrast to the notion that BCL6 functions to suppress
innate inflammation, we find that myeloid BCL6 deficiency diminished
lung inflammation without affecting viral loads. Using a series of Cre-
transgenic, reporter, and knockout mouse lines, we demonstrate
that BCL6 deficiency in neutrophils, but not in monocytes or lung
macrophages, attenuated host inflammation and morbidity following
IAV infection. Mechanistically, BCL6 bound to the neutrophil gene loci
involved in cellular apoptosis in cells specifically at the site of infection.
As such, BCL6 disruption resulted in increased expression of apoptotic
genes in neutrophils in the respiratory tract, but not in the circulation
or bone marrow. Consequently, BCL6 deficiency promoted tissue
neutrophil apoptosis. Partial neutrophil depletion led to diminished
pulmonary inflammation and decreased host morbidity. Our results
reveal a previously unappreciated role of BCL6 in modulating
neutrophil apoptosis at the site of infection for the regulation of host
disease development following viral infection. Furthermore, our
studies indicate that tissue-specific regulation of neutrophil survival
modulates host inflammation and tissue immunopathology during
acute respiratory viral infection.
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Influenza A virus (IAV) infection-associated diseases arelargely caused by a combination of the deleterious effects of
virus destruction and lung inflammation/injury resulted from
host immune response to clear the virus (1, 2). Neutrophils in-
filtrate into the lungs approximately 2 d post-IAV infection (3).
It has been suggested that neutrophils may play important roles
in facilitating viral clearance and disease resolution (4). Moreover,
evidence indicates that neutrophils facilitate the recruitment of
effector CD8+ T cells into the infected lungs to promote viral
clearance (5, 6). However, lung neutrophil accumulation has also
been correlated with disease severity following IAV infection (7).
The elevated numbers of recruited neutrophils may lead to the
enrichment of inflammatory/tissue- damaging signaling networks (8,
9). Therefore, the numbers of neutrophils at the infected lungs
must be tightly tuned to maximize efficient viral clearance while
minimizing immunopathology (10). In such settings, the initiation
of neutrophil apoptosis and consequent reduction in neutrophil
numbers may be advantageous to limit lung inflammation and by-
stander tissue injury (11). To this end, however, a direct link be-
tween excess neutrophil recruitment and/or survival and the extent
of pulmonary inflammation during IAV infection remains unclear.
Furthermore, the molecular mechanisms regulating neutrophil fate
and function during IAV infection, particularly at the infected site
(i.e., lungs), are largely elusive.
The proto-oncogene B cell lymphoma 6 (Bcl6) encodes a BTB/
POZ-zinc finger transcriptional repressor and is a master tran-
scriptional regulator critical for the development and function of
a number of immune cells (12). Beyond its role in T cell and B
cell responses (13), BCL6 has also been recognized as an an-
tagonist for NF-κB–mediated gene transcription to repress the
production of certain proinflammatory mediators in macro-
phages (14, 15). A recent report has suggested that BCL6 ex-
pression in macrophages may repress the antiviral type I IFN
production through its inhibition in IFN-regulatory factor 7
(Irf7) expression (16). However, the physiological function of
BCL6 in regulating antiviral innate immune responses is cur-
rently unknown, since BCL6 germ line-deficient mice exhibit
severe inflammation and autoimmunity (17).
Besides macrophages, the roles of BCL6 in regulating the re-
sponses of other myeloid cell populations, including neutrophils,
have not been examined before. Here we have addressed the func-
tion of BCL6 in regulating innate immune responses and influenza
viral pathogenesis using various conditional gene-deleted mice. We
demonstrate that BCL6 expression in neutrophils was critical to
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modulate neutrophil apoptosis in the lungs, but not in the circulation
or bone marrow. Our studies suggest that prolonged tissue neutro-
phil survival, regulated by BCL6, is a critical contributor to lung
immunopathology and host morbidity following IAV infection.
Results and Discussion
Myeloid BCL6 Deficiency Protects Hosts From IAV Infection Independent
of IFNAR1 Signaling. To explore the cell type-specific roles of BCL6
in regulating antiviral responses, we generated myeloid cell-specific
BCL6-deficient mice (Bcl6ΔLyz2). The Bcl6ΔLyz2 mice and littermate
control mice (Bcl6fl/fl) were monitored for outcomes after intranasal
inoculation with a sublethal dose of IAV (A/PR8/34 strain; PR8).
Compared with the Bcl6fl/fl mice, the Bcl6ΔLyz2 mice exhibited
drastically decreased weight loss and enhanced host recovery fol-
lowing sublethal PR8 infection (Fig. 1A). We also challenged the
mice with a lethal dose of PR8. Approximately 70% of Bcl6fl/fl mice
succumbed to infection, whereas all Bcl6ΔLyz2 mice survived (Fig.
1B). The BTB domain of BCL6 is responsible for the recruitment
of transcriptional corepressors. Mice engineered to express a BCL6
BTB mutant that cannot bind to corepressors show disruption of
certain BCL6 functions in vivo (18). We found that mice expressing
BCL6 BTB mutant (Bcl6BTB) had diminished host morbidity and
increased weight recovery following PR8 infection (Fig. 1C).
During viral infection, interferons (IFNs) are suggested to limit
viral replication and promote an antiviral state for the host in
the days early post-IAV infection (19). A recent report has suggested
that BCL6 inhibition in macrophages could lead to enhanced type I
IFN production on vesicular stomatitis virus infection (16). We
evaluated IFN-α and IFN-λ levels in the lungs and bronchoalveolar
lavage (BAL) fluid at 1 and 2 d postinfection (dpi). Bcl6ΔLyz2 mice
showed comparable production of IFN-α and modest reduction of
IFN-λ in the lungs and BAL fluid compared with littermate control
mice (Fig. 1D and SI Appendix, Fig. S1A). Furthermore, the ex-
pression levels of IFN-stimulated genes, including Isg15, Ifitm3, and
Mx1, were similar in the lungs of Bcl6ΔLyz2 and Bcl6fl/fl mice at 1 and
2 dpi (SI Appendix, Fig. S1B). These data suggest that type I IFNs
are probably dispensable for the enhanced protection against IAV
infection observed in myeloid BCL6-deficient mice.
To test this hypothesis more critically, we infected Bcl6ΔLyz2 or
Bcl6fl/fl mice lacking expression of type I IFN receptor (Ifnar−/−)
with PR8 and monitored disease severity. Indeed, loss of Ifnar1
expression in Bcl6ΔLyz2 or Bcl6fl/fl mice did not result in signifi-
cantly increased morbidity following PR8 infection (Fig. 1E). To
exclude the possibility that abnormalities due to the genetic
deficiency of Ifnar1 could affect the outcomes, we treated
Bcl6ΔLyz2 and Bcl6fl/fl mice with either IFNAR1-blocking or
control antibody before and after PR8 infection. Anti-IFNAR1
treatment did not alter the morbidity of Bcl6ΔLyz2 or Bcl6fl/fl mice
compared with control antibody treatment (Fig. 1F). Notably, we
observed that IFNAR1 deficiency only modestly affected host
morbidity following PR8 infection in BCL6 WT mice (Fig. 1E).
This observation is likely due to the viral evasion of type I IFN
responses following PR8 infection (20) and/or the presence of
innate antiviral defenses (e.g., type III IFNs) independent of type
I IFN signaling (21). Of note, the deficiency in IFNAR1 has been
shown to protect severe acute respiratory syndrome coronavirus
infection (22). Together, these data suggest that BCL6 expres-
sion in myeloid cells is critical for modulating the host response
to IAV infection, independent of the IFNAR signaling pathway.
Myeloid BCL6 Deficiency Diminishes Pulmonary Inflammation. During
acute respiratory viral infection, the deleterious effects of viral
replication contribute to pathogenesis (1, 23). However, we ob-
served comparable viral titers in Bcl6ΔLyz2 and Bcl6fl/fl mice and
equal rates of viral clearance (Fig. 2A). The infectious viruses were
completely cleared in both strains of mice at 10 dpi. (Fig. 2A).
Consistent with the viral clearance data, Bcl6ΔLyz2 and Bcl6fl/fl mice
exhibited similar kinetics and magnitude of IAV-specific T cell
responses in the lungs (Fig. 2B and SI Appendix, Fig. S1 C and D).
These results suggest that the enhanced resistance of Bcl6ΔLyz2 mice
to IAV infection is probably independent of viral burden.
Since the lung inflammation and injury resulting from the host’s
excessive immune response to IAV contribute to host disease de-
velopment (22–24), we next evaluated whether myeloid BCL6 reg-
ulates inflammatory responses during PR8 infection. We analyzed
the levels of cytokines and chemokines in the BAL fluid of
Bcl6ΔLyz2 and Bcl6fl/fl mice at 2, 4, or 10 dpi by multiplex assay. A
number of inflammatory cytokines and chemokines were signifi-
cantly decreased in the BAL fluid of Bcl6ΔLyz2 mice, particularly at 4
and 10 dpi (Fig. 2C and SI Appendix, Fig. S1E). These data suggest
that myeloid BCL6 deficiency diminishes pulmonary inflammation
following IAV infection in vivo. Bcl6ΔLyz2 mice also exhibited di-
minished accumulation of inflammatory immune cells, including
neutrophils and inflammatory monocytes, in the respiratory tract
(Fig. 2D and E and SI Appendix, Fig. S1F), which has been shown to
contribute to pulmonary immune pathology and mortality following
IAV infection (1, 22, 23, 25). Notably, no differences in the number
of neutrophils and inflammatory monocytes were detected in the
respiratory tract of Bcl6ΔLyz2 and Bcl6fl/fl mice at the baseline (Fig. 2
D and E), but those cells in the respiratory tract of Bcl6ΔLyz2 mice
were significantly reduced starting at 4 dpi. (Fig. 2 D and E). These
results suggest that the decreased morbidity observed in Bcl6ΔLyz2
mice to IAV infection is possibly due to decreased host inflamma-
tion rather than to viral burden following IAV infection.
Neutrophil BCL6 Deficiency Results in Diminished Host Inflammation
and Morbidity. Lyz2-cre–mediated gene recombination occurs
mainly in myeloid cells, including macrophages, neutrophils, and, to
a lesser extent, CD11b+ monocyte populations, following IAV in-
fection (26) (SI Appendix, Fig. S2A). Thus, we sought to identify the
cell types that expressed BCL6 and modulated host inflammation
during IAV infection. We first crossed Bcl6fl/fl mice to CD11c-cre
Fig. 1. Myeloid BCL6 deficiency enhances host resistance to severe IAV in-
fection. (A) Bcl6ΔLyz2 and Bcl6fl/fl mice were infected with sublethal PR8, and
host morbidity (% of initial weight) was monitored. (B) Bcl6ΔLyz2 and Bcl6fl/fl
mice were infected with lethal PR8, and host mortality was monitored. (C)
Bcl6BTB and C57BL/6 WT (control) mice were infected with sublethal PR8, and
host morbidity was monitored. (D) IFN-α concentrations were measured in
lung homogenate and BAL fluid of PR8-infected Bcl6ΔLyz2 and Bcl6fl/fl mice at
1 and 2 dpi (n = 4–6). (E) Mice with indicated genotypes were infected with
sublethal PR8, and host morbidity was monitored. (F) Host morbidity of PR8-
infected Bcl6ΔLyz2 and Bcl6fl/fl mice treated with anti-IFNAR or control anti-
body. In A–C, E, and F, data are pooled from at least two independent ex-
periments. In D, data are representative of two independent experiments.
Statistical differences are indicated. *P < 0.05; **P < 0.01; ***P < 0.001.
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transgenic mice to generate Bcl6ΔCD11c mice, in which BCL6 was
disrupted in CD11c-expressing alveolar macrophages and dendritic
cells. We also crossed Bcl6fl/fl mice to CX3CR1-cre transgenic mice
to generate Bcl6ΔCX3CR1 mice, in which BCL6 was disrupted in
both alveolar macrophages, CD11b+Ly6C− monocytes and mac-
rophages, and partially in Ly6C+monocytes (27, 28). We confirmed
the reported gene recombination in CD11c-cre and CX3CR1-cre
transgenic mice (SI Appendix, Fig. S2 B and C). Interestingly,
Bcl6ΔCD11c and Bcl6ΔCX3CR1 mice lost comparable amounts of
weight compared with their WT littermate controls following PR8
infection (Fig. 3 A and B), suggesting that BCL6 deficiency in
macrophages or Ly6C− monocytes does not alter mouse morbidity
during IAV infection.
To study the contribution of inflammatory monocytes (Ly6C+
monocytes) in regulating influenza-associated diseases in Bcl6ΔLyz2
mice, we crossed Bcl6ΔLyz2 and Bcl6fl/fl mice to Ccr2−/− mice to
block inflammatory monocytes trafficking to infected lungs (25, 29).
Consistent with a previous report (30), CCR2 deficiency did not
affect host weight loss in WT mice. CCR2 deficiency also did not
alter host morbidity in Bcl6ΔLyz2 mice (Fig. 3C), suggesting that
lung inflammatory monocyte infiltration is not required for the
phenotypes observed in Bcl6ΔLyz2 mice following IAV infection.
We next sought to determine whether BCL6 expression in neu-
trophils is responsible for the modulation of host disease during
infection. To this end, we observed that neutrophils expressed de-
tectable BCL6 following staining with BCL6 Ab or using BCL6-
YFP reporter mice (Fig. 3D). We then crossed Bcl6fl/fl mice with
MRP8-cre mice to generate Bcl6ΔMRP8 mice to delete BCL6 in
neutrophils. We confirmed that MRP8-cre targeted mainly neu-
trophils but not other myeloid cells (28) (SI Appendix, Fig. S2D).
Bcl6ΔMRP8 mice showed significantly lower host morbidity than
control mice following a sublethal dose of PR8 infection (Fig. 3E).
We also challenged the mice with a lethal dose of PR8. Strikingly,
80% of Bcl6fl/fl mice succumbed to lethal PR8 infection, whereas
approximately 80% of Bcl6ΔMRP8 mice survived (Fig. 3F). Bcl6ΔMRP8
mice exhibited similar kinetics of infectious virus clearance as
control mice (Fig. 3G). Consistent with the viral clearance data,
Bcl6ΔMRP8 mice had comparable numbers of T cell responses in
the lungs as control mice (Fig. 3H and SI Appendix, Fig. S2 E–G).
We next examined the effects of neutrophil BCL6 deficiency on
the accumulation of inflammatory mediators in the airway during
IAV infection. Loss of BCL6 in neutrophils resulted in diminished
levels of inflammatory cytokines and chemokines in Bcl6ΔMRP8
mice compared with Bcl6fl/fl mice at 3 and 9 dpi (Fig. 3I). Collec-
tively, the loss of BCL6 in neutrophils rather than in dendritic cells,
macrophages, or monocytes significantly protected the mice from
severe IAV infection. Of note, Bcl6ΔMRP8 mice appeared to de-
velop modestly more severe disease during sublethal IAV infection
and showed relatively less protection against lethal IAV infection
compared with Bcl6ΔLyz2 mice. Thus, the deficiency of BCL6 in
Fig. 2. Myeloid BCL6 promotes pulmonary inflammation following IAV in-
fection. (A–E) Bcl6ΔLyz2 and Bcl6fl/fl mice were infected with sublethal PR8.
(A) Viral titers in BAL fluid were monitored over time. Each point represents
one animal. (B) Lung IAV-specific NP366 and PA224 tetramer
+ CD8+ T cells at 6
and 10 dpi. (C) Cytokine and chemokine concentrations were quantified by
multiplex assay at 4 and 10 dpi (n = 6). (D and E) Flow cytometry quantifi-
cation of neutrophils (CD11b+Ly6G+) (D) and inflammatory monocytes
(CD11b+Ly6G−Ly6c+) (E) in the lungs. In A and C, data are pooled from two
independent experiments. In B, D, and E, data are representative of at least
two independent experiments (n = 4–6 mice/group/experiment). Statistical
differences are indicated. *P < 0.05; **P < 0.01; ***P < 0.001. n.s., not sig-
nificant. n.d., not detected.
Fig. 3. Neutrophil BCL6 deficiency decreases host inflammation and morbid-
ity. (A) Bcl6ΔCD11c and Bcl6fl/fl mice were infected with sublethal PR8, and host
morbidity (% of initial weight) was monitored. (B) Bcl6ΔCX3CR1 and Bcl6fl/fl mice
were infected with sublethal PR8, and host morbidity was monitored. (C) Mice
with indicated genotypes were infected with sublethal PR8, and host morbidity
was monitored. (D) Flow cytometry analysis of BCL6 expression, with BCL6
staining in neutrophils (Upper) and YFP expression in neutrophils in WT and
BCL6-YFP reporter mice (Lower). (E) Bcl6ΔMRP8 and Bcl6fl/fl mice were infected
with sublethal PR8, and host morbidity wasmonitored. (F) Bcl6ΔMRP8 and Bcl6fl/fl
mice were infected with lethal PR8, and host mortality was monitored. (G–I)
Bcl6ΔMRP8 and Bcl6fl/fl mice were infected with sublethal PR8. (G) Viral titers in
the BAL fluid over time (n = 4–7). (H) Lung IAV-specific NP366 and PA224 tet-
ramer+ CD8+ T cells at 6 and 9 dpi. (I) Cytokine and chemokine concentrations
were quantified by multiplex assay at 3 and 9 dpi (n = 6). In A–C and E, data are
pooled from at least two independent experiments. In D and H, data are
representative of two independent experiments (n = 4–6 mice/group/experi-
ment). Statistical differences are indicated. *P < 0.05; **P < 0.01; ***P < 0.001.
n.s., not significant. n.d., not detected.
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other myeloid cells may “aid” neutrophil BCL6 deficiency to
maximally protect the host from IAV-induced inflammation
and diseases.
BCL6 Represses Apoptotic Gene Expression in Neutrophils Specifically
at the Site of Infection. To gain insight into why loss of BCL6
expression in neutrophils resulted in decreased inflammatory
responses and enhanced host resistance to IAV infection, RNA
sequencing was performed to profile the transcriptional signa-
tures in neutrophils from lungs of PR8-infected Bcl6ΔMRP8 and
Bcl6fl/fl mice. Approximately 133 genes were down-regulated and
294 genes were up-regulated in BCL6-deficient neutrophils vs.
WT neutrophils (Fig. 4A).
To further characterize these differences, we performed gene
set enrichment analysis on the gene expression profiles using the
hallmark collection of the Molecular Signatures Database. The
loss of BCL6 expression in neutrophils resulted in significant
enrichment of both the inflammatory response and TNF sig-
naling via NF-κB gene sets compared with WT neutrophils (Fig.
4B and SI Appendix, Fig. S3A), suggesting that BCL6 suppresses
inflammatory cytokine expression in neutrophils following IAV in-
fection. These data are consistent with previous reports that BCL6
suppresses proinflammatory mediators in macrophages, possibly
through inhibition of NF-κB transcriptional activity (14, 15).
Although we observed increased enrichment of mRNA for the
inflammatory response in neutrophils from BCL6-deficient mice
(Fig. 4B and SI Appendix, Fig. S3A), the overall protein levels of
proinflammatory cytokines and chemokines were significantly
lower in the lungs of BCL6-deficient mice (Fig. 3I). Thus, we
postulated that the diminished pulmonary inflammation ob-
served in Bcl6ΔMRP8 mice may be related to the decreased
neutrophil numbers but not to the diminished expression of in-
flammatory cytokines on a per cell basis. Consistent with this
hypothesis, genes associated with apoptosis signature were sig-
nificantly up-regulated in neutrophils from Bcl6ΔMRP8 mice
compared with Bcl6fl/fl mice (Fig. 4C). In germinal center B cells,
BCL6 has been reported to suppress expression of the P53
tumor-suppressor gene and modulate the P53-dependent apo-
ptotic response (31). Consistently, BCL6 repressed gene signa-
tures in P53 pathway in neutrophils following IAV infection (Fig.
4D). Indeed, the P53 pathway has been shown to regulate neu-
trophil apoptosis in the tissue (32). Analysis of the core genes
from apoptosis gene sets indicated up-regulation of certain
apoptosis-related genes in BCL6-deficient neutrophils, including
Pmaip1 (encodes Noxa), Casp3, and Pdcd4 (Fig. 4E, genes
marked in red). We confirmed that BCL6-deficient neutrophils
in the BAL fluid exhibited enhanced Pmaip1, Casp3, and Pdcd4
expression compared with their WT counterparts through
quantitative RT-PCR (Fig. 4F). Interestingly, BCL6-deficient
neutrophils isolated from the blood or bone marrow showed
comparable Pmaip1, Casp3, and Pdcd4 expression as their WT
counterparts (Fig. 4F), suggesting that BCL6 controls apoptotic
gene expression specifically at the site of infection.
We next sought to determine the underlying mechanisms by
which BCL6 controls apoptotic gene expression in neutrophils at
the infection site, but not in the circulation or in the bone
marrow. We first examined BCL6 expression levels in the bone
marrow, blood, and infected lungs and found that neutrophils in
the bone marrow and blood had comparable BCL6 expression to
that of their counterparts in the lungs, kidney, and liver before
and after IAV infection (Fig. 4G and SI Appendix, Fig. S3B),
suggesting that the tissue-specific effects of BCL6 in controlling
neutrophil apoptotic gene expression are not due to differential
BCL6 expression levels. BCL6 acts mainly as a transcriptional
repressor to modulate gene expression (33).
We next asked whether BCL6 was recruited to the loci of
apoptotic genes in neutrophils, and whether the recruitment was
subject to tissue-specific regulation. We performed a chromatin
immunoprecipitation (ChIP) assay for BCL6 in neutrophils pu-
rified from the infected lungs or the bone marrow. Due to the
large numbers of cells required for the ChIP assay, we did not
perform BCL6 ChIP analysis in blood neutrophils. Strikingly,
BCL6 robustly bound to the Casp3 and Pmaip3 loci, and to a
lesser extent to the Pdcd4 locus, in neutrophils isolated from the
infected lungs (Fig. 4H). However, BCL6 showed limited binding
to these gene loci in neutrophils isolated from the bone marrow,
even though bone marrow neutrophils expressed robust BCL6
(Fig. 4 G and H). Thus, BCL6 appears to control apoptotic gene
transcription in a tissue type-specific fashion in neutrophils,
which explains the specific increase of apoptotic gene expression
in tissue neutrophils but not in the circulation or the bone
marrow following BCL6 deficiency.
Fig. 4. BCL6 represses apoptotic gene expression in neutrophils of lungs
following IAV infection. (A–E) Transcriptomic data for lung neutrophils
sorted from Bcl6ΔMRP8 and Bcl6fl/fl mice infected with sublethal PR8 at 6 dpi.
(A) Heat map of 427 out of 11,523 RNA transcripts differentially expressed in
neutrophils. (B–D) Enrichment plots from gene set enrichment analysis of
BCL6-deficient neutrophils compared with WT neutrophils using the hall-
mark gene set collection from the Molecular Signatures Database. (E) mRNA
expression (normalized log2) of core genes from apoptosis gene sets in lung
neutrophils from Bcl6ΔMRP8 and Bcl6fl/fl mice. Red and blue represent over-
expressed and underexpressed genes, respectively. (F) Casp3, Pmaip1, and
Pdcd4 transcript levels in neutrophils of BAL fluid, blood, and bone marrow
from Bcl6ΔMRP8 and Bcl6fl/fl mice infected with PR8 at 6 dpi were analyzed by
RT-PCR. Neutrophils were harvested from four mice per genotype and
pooled for gene expression studies. (G) Representative flow cytometry plots
of BCL6 expression showing BCL6 staining in neutrophils of bone marrow,
blood, and lung from naïve mice and PR8-infected mice at 6 dpi (n = 4). (H)
ChIP analysis of BCL6 enrichment relative to input chromatin in lung and
bone marrow neutrophils of PR8-infected WT mice at 6 dpi. The annotated
gene names and positions of the BCL6-binding sites relative to the tran-
scription start sites are listed. Neutrophils were harvested from 10 mice and
pooled for ChIP studies.
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BCL6 Regulates Tissue Neutrophil Cellular Apoptosis. Previous stud-
ies have shown that IAV infection induces neutrophil apoptosis
(34). Our RNA-sequencing data also indicate that gene signatures
implicated in apoptosis process were up-regulated in neutrophils
from Bcl6ΔMRP8 mice, suggesting that BCL6-deficient neutrophils
may undergo enhanced cell death compared with control WT
neutrophils. To examine this idea, we measured neutrophil apo-
ptosis in Bcl6ΔLyz2, Bcl6ΔMRP8 and Bcl6fl/fl mice by FACS analysis
using propidium iodide (PI) or Annexin V staining on PR8 in-
fection. The percentage of apoptotic neutrophils (Annexin V+/PI−)
was higher in BAL fluid and lungs from Bcl6ΔLyz2 and Bcl6ΔMRP8
mice compared with Bcl6fl/fl mice, whereas inflammatory monocyte
apoptosis remained unchanged (Fig. 5A and SI Appendix, Fig. S3 C
and D). Notably, lung neutrophil apoptosis was comparable in
Bcl6fl/fl and Bcl6ΔMRP8 mice without PR8 infection (SI Appendix,
Fig. S3E). These data suggest that BCL6 is critical to the control of
neutrophil apoptosis in the lungs following IAV infection. To fur-
ther confirm this notion, we also assessed active caspase 3/7
activity in neutrophils following PR8 infection. BCL6 deficiency
resulted in increased caspase 3/7 activity in the respiratory tract
but not in the bone marrow (SI Appendix, Fig. S3F), further
suggesting that BCL6 deficiency promotes neutrophil apoptosis
at the site of infection.
We next determined whether neutrophils in bone marrow and
blood were similarly affected in Bcl6ΔMRP8 and Bcl6fl/fl mice.
Strikingly, no significant differences in the percentage of apoptotic
neutrophils in bone marrow or blood were observed between
Bcl6ΔMRP8 or Bcl6fl/fl mice (Fig. 5 B and C and SI Appendix, Fig.
S4A). Thus, BCL6 modulates neutrophil survival specifically in the
lungs following IAV infection.
To determine whether the increased lung neutrophil apoptosis
observed in neutrophil-specific BCL6-deficient mice is influenza-
strain specific, we infected Bcl6ΔMRP8 or Bcl6fl/fl mice with influenza
A/X31 (X31, H3N2) strain and assessed neutrophil apoptosis in the
BAL fluid, lung, blood, and bone marrow. Loss of BCL6 on X31
infection increased neutrophil apoptosis in the BAL fluid and lung
but not in bone marrow or blood (SI Appendix, Fig. S3G). These
results demonstrate that BCL6 deficiency-promoted lung neutro-
phil apoptosis is not viral strain-specific. The frequencies of mature
neutrophils in bone marrow and blood were similar in Bcl6ΔMRP8
and Bcl6fl/fl mice (SI Appendix, Fig. S4B).
Next, we sought to determine whether a difference in neu-
trophil survival contributes to neutrophil accumulation in the
lungs of Bcl6ΔMRP8 and Bcl6fl/fl mice. To do so, we quantified
neutrophil numbers in the lungs and BAL fluid following PR8
infection. The Bcl6ΔMRP8 mice had lower numbers of neutrophils
in the lung and BAL fluid, particularly at 4 and/or 6 dpi (Fig. 5D
and SI Appendix, Fig. S4C), which marks the peak neutrophil
levels in both groups, ruling out a delayed neutrophil response in
Bcl6ΔMRP8 mice. Therefore, increased apoptosis of neutrophils
in the lungs of BCL6-deficient mice resulted in the decrease of
those cells in the respiratory tract following IAV infection.
Excess Neutrophils Drive Pulmonary Inflammation. Although exu-
berant neutrophil recruitment has been associated with en-
hanced host morbidity and detrimental inflammation (7, 8), the
direct link between excessive neutrophil recruitment and pul-
monary inflammation following IAV infection has been missing.
To explore this, we partially depleted pulmonary neutrophils
during the early phase of IAV infection using a low dose of a
neutrophil-depleting antibody (anti-Ly6G, 25 μg/mouse). Here
the limited anti-Ly6G–based neutrophil depletion caused roughly
50% decrease in the number of lung neutrophils without affecting
inflammatory monocytes during infection (Fig. 5E and SI Ap-
pendix, Fig. S4D). Mice with reduced neutrophil numbers showed
diminished morbidity to PR8 infection compared with mice with
normal neutrophil levels (Fig. 5F), a phenotype similar to that of
Bcl6ΔMRP8 mice (Fig. 3E).
We also measured cytokine and chemokine levels in the BAL
fluid of mice treated with or without anti-Ly6G at 3 and 9 dpi
(Fig. 5G). A number of inflammatory cytokines and chemokines
were decreased in the BAL fluid of anti-Ly6G–treated mice (Fig.
5G), similar to observations in Bcl6ΔMRP8 mice (Fig. 3I). These
data suggest that excessive accumulation of neutrophils in the
lungs drives an exaggerated inflammatory response and increases
disease severity following IAV infection. Consistently, dysregu-
lated neutrophil responses in the lungs led to the accumulation
of inflammatory damaging signaling networks, which act as an
important driver of H1N1 IAV-induced lethality (8). Of note,
neutrophils may contribute to viral clearance and adaptive im-
munity (3, 6, 35). Indeed, previous data show that total ablation
of neutrophils by the injection of a higher dose of anti-Ly6G
promotes host mortality (4, 36), although it is possible that
high-dose anti-Ly6G antibody may cause bystander deletion of
Ly6Glow non-neutrophil cells that are important in antiviral re-
sponses (8). Nevertheless, our data are consistent with previously
reported findings that the attenuation of deleterious neutrophil
responses with low doses of anti-Ly6G provides protection
against lethal IAV infection (8). Our data and the findings
reported by Brandes et al. (8) support the view that early en-
gagement of neutrophils instigates a damaging feedforward innate
inflammatory circuit responsible for severe disease development
following IAV infection.
Fig. 5. Attenuation of neutrophils ameliorates host inflammation. (A–C)
Bcl6ΔMRP8 and Bcl6fl/fl mice were infected with sublethal PR8. (A) Neutrophil
apoptosis stained with Annexin V and PI in the BAL fluid and lung at 2 dpi.
Representative flow cytometry plots (Left) and the percentages of apoptotic
neutrophils (Annexin V+ PI−) (Right) are shown. (B and C) Neutrophil apo-
ptosis stained with Annexin V and PI in the bone marrow (B) and blood (C) at
2 dpi. The percentages of apoptotic neutrophils (Annexin V+ PI−) are shown.
(D) Absolute numbers of neutrophils in the BAL fluid and lung from
Bcl6ΔMRP8 and Bcl6fl/fl mice infected with PR8 over time. Data are represen-
tative of three independent experiments (n = 4–6 mice/group/experiment).
(E–G) C57BL/6 mice treated with anti-Ly6G antibodies or isotype antibodies
were infected with sublethal PR8. (E) Representative flow cytometry plots
showing the percentage of lung neutrophils at 3 dpi (n = 3–4). (F) Host
morbidity (% of initial weight) was monitored. (G) Cytokine and chemokine
concentrations were quantified by multiplex assay at 3 and 9 dpi (n = 3–4).
Statistical differences are indicated. *P < 0.05; **P < 0.01; ***P < 0.001. n.d.,
not detected. n.s., not significant.
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Neutrophils are the first responders to infiltrate the sites of in-
fection to clear bacterial infections (37, 38). In this regard, en-
hanced tissue neutrophil apoptosis caused by BCL6 deficiency may
increase pulmonary bacterial burden and worsen outcome during
certain respiratory bacterial infections, such as Staphylococcus
pneumonia infection (37, 38). Conversely, excessive neutrophil re-
cruitment is a hallmark of acute susceptibility to Mycobacterium
tuberculosis and is associated with overexuberant inflammatory re-
sponse and disease progression (39). In this case, loss of neutrophil
BCL6 may provide benefits to decrease tissue damage during M.
tuberculosis infection. Thus, the precise roles of neutrophil BCL6 in
modulating differential disease outcomes following respiratory in-
fections may ultimately depend on the type of pathogen.
In conclusion, we have identified a role for BCL6 in modulating
neutrophil survival in the tissue, thereby regulating the severity of
diseases following IAV infection. Furthermore, our studies indicate
that neutrophil survival is tightly regulated specifically at the sites of
infection, thereby influencing host inflammation and tissue immu-
nopathology during acute respiratory viral infection. An important
unanswered question is why the enhanced neutrophil death fol-
lowing BCL6 deficiency is restricted to the lungs and does not occur
in the blood or bone marrow. To this end, our data show that BCL6
could bind to Pmaip1 (encoding Noxa) promoter, and that BCL6
deficiency resulted in increased levels of Pmaip1 in lung neutro-
phils. Noxa is a BH3-only protein that can bind and trigger
proteasome-mediated degradation of the prosurvival protein Mcl-1
(myeloid cell factor 1) (40), which plays essential roles in neutrophil
survival (38, 41). Notably, lung neutrophils express higher Noxa
levels than blood and bone marrow neutrophils in WT mice,
whereas BCL6 deficiency further increases Noxa expression spe-
cifically in the lungs. Thus, it is possible that enhanced Noxa ex-
pression promotes lung neutrophil apoptosis through antagonizing
Mcl-1 expression and/or function in BCL6-deficient neutrophils.
Further studies are needed to test this possibility. Further studies
are also warranted to elucidate the exact downstream mechanisms
by which live neutrophils contribute to host inflammation and injury
following IAV infection. The development of pharmacologic agents
that target neutrophil survival and function in the tissue may be
promising to decrease host inflammation and minimize lung injury
for the treatment of severe IAV infection.
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All animal experiments were approved by the Institutional Animal Care and
Use Committees of Indiana University School ofMedicine and theMayo Clinic.
The animals, virus infection, experimental setup, sample collection, and
statistical analysis are described in detail in SI Appendix, Materials
and Methods.
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